Memo Therapeutics raises CHF 2.3m series-A

EVA Basel and Zürcher Kantonalbank also backed the company. The funds will be used to further develop and validate the company's antibody discovery platform.

Redalpine invested via its Redalpine Fund II, which closed in June 2012 on CHF 80m. In April 2015, Redalpine was part of the €10m series-A for German banking app Number26.

Company
Founded in 2014, Memo Therapeutics is a spinout from Swiss Federal Institute of Technology Zurich. The company is developing technology enabling the extraction and recombinant expression of the antibody genetic information of B cells. The cloned antibodies could potentially be used for the treatment of infectious diseases, cancers and allergies.

People
Redalpine partner Michael Sidler and EVA managing director Peter Burkhardt have joined Memo Therapeutic's board of directors. Armin Mäder is the CEO of Memo Therapeutics.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Healthcare
• Early-stage
• Switzerland
• seed